EP3057592A1 - Effecteurs d'assemblage de virus de l'hépatite b - Google Patents

Effecteurs d'assemblage de virus de l'hépatite b

Info

Publication number
EP3057592A1
EP3057592A1 EP14853713.7A EP14853713A EP3057592A1 EP 3057592 A1 EP3057592 A1 EP 3057592A1 EP 14853713 A EP14853713 A EP 14853713A EP 3057592 A1 EP3057592 A1 EP 3057592A1
Authority
EP
European Patent Office
Prior art keywords
group
compound
reaction
composition according
tlc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14853713.7A
Other languages
German (de)
English (en)
Other versions
EP3057592A4 (fr
EP3057592B1 (fr
Inventor
Adam Zlotnick
Lichun Li
William TURNER Jr.
Samson FRANCIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of EP3057592A1 publication Critical patent/EP3057592A1/fr
Publication of EP3057592A4 publication Critical patent/EP3057592A4/fr
Application granted granted Critical
Publication of EP3057592B1 publication Critical patent/EP3057592B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Definitions

  • HBV Hepatitis B
  • liver cancer hepatocellular carcinoma
  • interferon a or pegylated interferon the only FDA approved alternative to antiviral nucleoside/nucleotide analogs is treatment with interferon a or pegylated interferon, .
  • interferon a or pegylated interferon the adverse event incidence and profile of inter.fero.n-a can result in poor tolerability, and many patients are unable to complete therapy.
  • only a small percentage of patients are considered appropriate for interferon therapy, as only a small subset of patients who present with low viral loads and transaminitis greater than 2x the upper limit of normal are likely to have a sustained clinical response to a year-long course of interferon therapy.
  • interferoo-based therapies are used in only a small percentage of all diagnosed patients who elect for treatment.
  • Nucleoside analogs suppress virus production, treating the symptom, but leave the infection intact. Interferon a has severe side effects and less iolerability among patients and is successful as a finite treatment strategy in only a small minority of patients. There is a clear on-going need for more effective treatments for HBV infections.
  • the present disclosure is directed in pan to 2,4-diaminopyrimidine compounds having activity against hepatitis B virus, for example, by affecting assembly of viral capsid proteins.
  • disclosed compounds may be considered CpAMs core protein a! foste ic modifiers— which can lead to defective viral capsid assembly.
  • CpAMs may affect steps "upstream" of capsid assembly by altering the concentrations of Cp (core protein) available as dinners as compared to capsid or other nrultirneric forms.
  • Disclosed compounds or CpAMs may noticeably affect functions upstream of viral assembly, such as interfering with cccDNA transcription, RNA stability and/or protein- protein interactions.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising', (i) a compound of Formula I having the structure:
  • X is selected from the group consisting of p and
  • q 0, 1 , 2, 3 or 4;
  • p 0, 1, 2, 3, or 4; is O, 1 , 2. 3, or 4;
  • R ! is independently for each occurrence selected from the group consisting of -H, ⁇ C
  • w 0, 1 or 2;
  • R' is independently for each occurrence selected from the group consisting of -H and ⁇ Cj-
  • R" is independently for each occurrence selected from the group consisting of ⁇ H and - CrC f> alkyl; or R' and R" are taken together with the nitrogen atom to which they are attached to form a 4-7 membered heterocyclic ring;
  • R " is independently for each occurrence selected from the group consisting of -11, ⁇ Ci- Csalk l, ⁇ C]-Qal.koxy, -Ci-C ⁇ ;aJkyI-0 ⁇ Ci-C6alkyl, halogen, cyano, -OH.
  • R* is selected from the group consisting of -H and -Ci-Gsalkyl
  • CrC «alkyl or Cj-Csalkoxy may be independently for each occurrence optionally substituted with, one, two, or three halogens;
  • the present disclosure provides a method of treating, ameliorating, preventing, or substantially delaying a hepatitis B viral infection in an individual, the method comprising administering to the individual a pharmaceutical composition disclosed herein.
  • Treating includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.
  • alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-6 or 3-4 carbon atoms, referred to herein for example as C-2-C-6 alkenyl, and CVC* alkenyl, respectively.
  • alkenyl groups include, but are not limited to, vinyl, aliyl, butenyl, entenyi, etc.
  • alkoxy refers to a straight or branched alky! group attached to an oxygen (a!kyl-O-).
  • exemplary alkoxy groups include, but are not limited to, groups with an alkyl group of 1-6 or 2-6 " carbon atoms, referred to herein as O-Ce alkoxy, and Cj-Q alkoxy, respectively.
  • exemplary alkoxy groups include, but are not limited to rnethoxy, ethoxy, isopropoxy, etc.
  • alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-6, 1-4, or 1-3 carbon atoms, referred to herein as CrQ > alkyl, CrC 4 alkyl, and Cj- alkyl, respectively.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methy - 1 -propyl, 2 ⁇ methyl-2- propyl, 2-raeth.yl- l -butyl, 3 -methyl- 1 -butyl, 3-methyl-2-butyL 2,2-dimethyl- i -propyl, 2-methyl- .1 -pentyl, 3-methy 1- 1 -pentyl, 4-methyl-l -pentyl, 2 ⁇ methyi-2-pentyl, 3-methyl-2-pe «tyl ., 4-methyl- 2-pentyl, 2,2-dlmef yl- 1 -butyl, 3,3-dtmethyl- 1 -butyl, 2-ethyl- -butyl, butyl, isobutyl, t-butyl, pentyl, isopenryl, neopentyl, he
  • alkytiyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-6, or 3-6 carbon atoms, referred to herein as C , alkynyl and C3-Q a ' lkynyl, respectively.
  • alkynyl groups include, but are not limited to, ethynyi propynyi, batynyl, pentynyl, hexynyl, methy!propynyl, etc.
  • cycloalkyP refers to a monocyclic saturated or partially unsaturated hydrocarbon group of, for example 3-6, or 4-6 carbons, referred to herein, e.g., as C3-C6 cycloalkyl or C3 ⁇ 4 ⁇ Cs cycloalkyl.
  • exemplary cycloalkyl groups include, bui are not limited to, cyclohexane, cyclohexene, cyelopentane, cyclobutane or, cyclopropane.
  • halo or halogen as used herein refer to F, CI, Br, or L
  • Phannaceutieally or pharmacologically acceptable include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
  • preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biologies standards.
  • compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.
  • composition refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers,
  • “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • the compounds of the invention can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, domestic animals ⁇ e,g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
  • the mammal treated in the methods of the invention is desirably a mammal in which treatment of hepatitis 8 is desired.
  • “Modulation” includes antagonism (e.g., inhibition), agonism, partial antagonism and/or partial agonism.
  • the term "therapeutically effective amount” means the amount of the subject compound ihat will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the compounds of the invention are administered in therapeutically effective amounts to treat a disease.
  • compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisu!fate, phosphate, acid phosphate, isonicotmate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bi tartrate, ascorbate, succinate, ma!eate, gentisinate, funiarate, glu
  • Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
  • Compounds included in the present compositions that include a basic or acidic moiety may also form pharmaceutically acceptable salts with various amino acids.
  • the compounds of the disclosure may contain both acidic and basic groups; for example, one amino and one carhoxyiic acid group. In such a case, the compound can exist as an acid addition salt, a zwitterion, or a base salt.
  • the compounds of the disclosure may contain one or more chiral center and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
  • stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R.” or “S,” depending on the configuration of substituents around the stereogemc carbon atom.
  • the present invention encompasses various stereoisomers of these compounds and mixtures thereof Stereoi somers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated ** ( ⁇ ) ** in nomenclature, but the ski lled artisan will recognize thai a structure may denote a chirai center implicitly.
  • the compounds of the disclosure may contain one or more chirai centers and/or double bonds and, therefore, exist as geometric isomers, enantiomers or diastereomers.
  • the enantiomer and diasiereomers may be designated by the symbols "( ⁇ + ⁇ ) > " "(-).' " or “S,” depending on the configuration of substituents around the stereogenic carbon atom, but the skilled artisan will recognize that a structure may denote a chirai center implicitly.
  • Geometric isomers resulting from the arrangement of substiiuents around a carbon-carbon double bond or arrangement of substiiuents around a cycloalkyl or heterocyclic ring, can also exist in the compounds of the present invention.
  • stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers.
  • the present invention encompasses various stereoisomers of these compounds and mixtures thereof
  • Stereoselective syntheses a chemical or enzymatic reaction in which a single reactant forms an unequal mixture of stereoisomers during the creation of a new stereocenter or during the transformation of a pre-existing one, are well known in the art.
  • Stereoselective syntheses encompass both enantio- and diastereoseiective n-ansformations.
  • Carreira and Kvaerao Classics in Stereoselective Synthesis, Wiley- VCH: Weinheim, 2009, ⁇ 0032 j
  • the compounds disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • the compound is amorphous.
  • the compound is a polymorph
  • the compound is in a crystalline form.
  • the invention also embraces isotopically-labeled compounds of the invention which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes thai can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 3 ⁇ 4 3 H, W C, 54 C, ⁇ 5 N, 3 ⁇ 4, i 0, 31 P, M P, 35 S, !3 ⁇ 4 F, and 3 ⁇ ; C1, respectively.
  • a compound of the invention may have one or more H atom replaced with deuterium.
  • Certain isotopically-labeled disclosed compounds e.g., those labeled with 3 ⁇ 4 and
  • Tritiated (i.e., H) and carbon- 14 (i.e., l C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitutio with heavier isotopes such as deuterium (te., ⁇ H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo halt-life or reduced dosage requirements) and hence may be preferred in some circumstances.
  • IsotopicalSy labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in the e.g., Examples herein by substituting an isotopkail labeled reagent for a non-isoiopically labeled reagent,
  • prodrug refers to compounds that are transformed m vivo to yield a disclosed compound or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
  • the transformation may occur by various mechanisms (such as by esterase, amidase, phosphatase, oxidative and or reductive metabolism) in various locations (such as in the intestinal lumen or upon transit of the intestine, blood or liver).
  • Prodrugs are well known in the art (for example, see Rautio, Kumpulainen, el al, Nature Reviews Drug Discovery 2008, 7, 255).
  • a pr odrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group, for example with a group such as ( €] ⁇ C$)alkyl 3 (CrC)2 ⁇ alkanoyioxyhurlryl, 1 -(alkanoyloxy )ethyl having from.
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Cs-Cslalkanoyloxymeihyl, l -((C's intends)aSkanoyloxy)ethyL I-methyl-l-((CrC fJ )aikanoyloxy)ethyi (Ci-Cf,)alk.oxycarbonyloxymeth.yi, N-(C
  • a prodrug can be formed, for example,, by creation of an amide or carbamate, an A3 ⁇ 4eyloxyakyi derivative. an (oxodioxoleayI)raethyl derivative, an N- annicb base, inline or enamine.
  • a secondary amine can be metabolically cleaved to generate a bioactive primary amine, or a tertiary amine can metabolically cleaved to generate a bioactive primary or secondary amine.
  • Tile present invention is based in part on the discovery of that certain classes of com pounds such as t hose described herein may acti vate assembl y of the viral capsid. independent of the norma! nucleating signals, e.g. act as core protein allosferic modulators having an effect against HBV.
  • disclosed compounds may activate assembly of the viral capsid independent of the normal nucleating signals.
  • Hepatitis B vims for example, consists of an envelope, a nucleoeapsid core, viral
  • the viral DNA is converted into a covalently-closed circular
  • cccDNA which codes for a pregenomic RNA (pg RNA) and other mRNAs.
  • the pregenomic RNA exported to the cytoplasm, codes for core protein and the reverse transcriptase. Encapsidation of the pregenomic RNA and the reverse transcriptase by core protein results in the formation of immature HBV cores which matiiraie as the pregenomic RN A is reverse transcribed to the circular and partially double stranded DNA, completing the cycle.
  • capsid assembly begins with an CpAM » Cp (Assembly effec ⁇ or " ore protein) complex instead of waiting for the biological RT « pgRNA nucleating complex; the resulting capsid is thus defective.
  • CpAMs can leverage consumptio of a few molecules needed tor nucieation to consume for example up to 1 17 Cp diniers.
  • CpAMs may have one or both of activities such as substantially interacting with or e.g., binding to Cp dimers, activating assembly, and/or substantially binding or interacting with capsids at e.g.. a higher affinity as compared to binding to the Cp dimer.
  • O042 Core proteins also have roles upstream of capsid assembly and are associated with nuclear cccDNA and affect their stability and transcription; they are involved in export of the pregenomic R A from the nucleus,
  • the compounds provided herein may affect virus assembly by interacting with core protein dimers as well as eapsids, and/or may affect core protein activity upstream of capsid assembly.
  • Defective assembly can immediately suppress virus production. Suppressed Cp activity upstream of assembly can also interfere with activities of the virus required for stability of the infection itself.
  • provided compounds may successfully treat HBV with a finite course of therapy (as opposed to the potentially life-long therapy necessary with current antiviral nucleosides/nucleotides), e.g. such finite therapy would result from a loss of new viral proteins and mRNA resulting from epigenetic modification of the viral cccDNA, as well as a reduction in new infectious virions.
  • disclosed compounds may activate viral capsid assembly independent of the normal nucleating signals leading to defect e assembly, capsid assembly begins with an AE » Cp complex instead of waiting for the biological RT*pgRNA nucleating complex; the resulting capsid or aberrant complex, e.g., cannot support production of a new virion.
  • disclosed compounds may leverage consumption of a few molecules needed for nucleation to consume up to 120 Cp dimers.
  • disclosed compounds may, for example, alter the concentration of Cp (core protein), likely required for activities upstream of capsid assembly. Suppressing Cp activity upstream of assembly interferes with the Cp interactions with the viral reservoir (cccDNA). This may lead to clearance of the infection by reduction of viral proteins and cccDNA activity'',
  • composition comprising; (i) a compound of Formula 1 ha ving the structure:
  • q 0, 1, 2. 3 or 4;
  • p 0, L 2, 3, or 4;
  • r 0, 1, 2, 3, or 4;
  • R l is independently for each occurrence selected from the group consisting of -H, -CV
  • w 0, 1 or 2;
  • R' is independently for each occurrence selected from the group consisting of -H and -C Cijalkyl
  • .R is independently for eac occurrence selected from the group consisting of -H and - C ⁇ -C f. ;alkyl; or R' and R" are taken together with the nitrogen atom to which they are attached to form a 4-7 membered heterocyclic ring;
  • R 2 is independently for each occurrence selected from the group consisting of -H, -C € 6 alkyJ, -Ci-Qalkoxy, -Ci-Csalkyi-O-d-Csalkyl, halogen, cyano, -OH, -C(Q)H.
  • ' is selected from the group consisting of -H and -CVC ⁇ alkyl
  • Cj -Chalky! or Ct-Cgalkoxy may he independently for eac occurrence optionally substituted with one, two ; or three halogens;
  • p is 1 or 2.
  • the compound of Formula 1 is represented b Formula 1-
  • R ! is independently for each occurrence selected from the group consisting of -H, ⁇ C
  • R ⁇ is independently for each occurrence selected from the group consisting of -H and halogen
  • R" is independently for each occurrence selected from the group consisting of -H, -Ci- Qalkyl, -Cj-Csalkoxy, -Ci-Qalkyl-O-CVQalkyl, halogen, cyano, -OH, - €(0) 1, -C0 2 R', - C(0)N ⁇ R')(R"), -C(0)CrC6alkyl, - R')(R") 5 -N0 2? -N(R')C(0)Ci-Gialky!, -S(0) w -Cr Cealky!, -N(R S(OVCj-C «alkyi, and -S(OVN(R')(R");
  • R "" ' is independently for each occurrence selected from the group consisting of -H, ⁇ Ci- Csalk l, -C]-Qa1.koxy, -Cj-Qalkyl-O-Ci-Oiaikyl, halogen, cyano, -OH.
  • R * * is independently for each occurrence selected from the group consisting of-H and halogen
  • R " is independently for each occurrence selected from the group consisting of -H, -CV Qaikyk -Ci-C'calkoxy, -Ci-C «alkyl-0-C ⁇ -O#!kyl, halogen, cyano, -OH, -C(0)H 5 -CO2R', - C(0)N ⁇ R')(R"), -C ⁇ 0)Ci-Olkyl, -N(R ') ⁇ 3 ⁇ 4"), -NO3 ⁇ 4 ⁇ N(R i )C(0)CrC i! ai-kyl 3 -S(0)wCi- C 6 aIkyL
  • q 0, .1 , 2, 3 or 4;
  • R' is independently for each occurrence selected from the group consisting of -H and -C3 ⁇ 4- C ⁇ alky!;
  • R" is independently for each occurrence selected from the group consisting of -H and - Cj-Cealkyi; or R' and R" are taken together with the nitrogen atom to which they are attached to form a 4-7 membered heterocyclic ring;
  • R ':' is selected from the group consisting of-H and -Cj-Csalkyl
  • Cj-Qalkyl or Ci-Csalkox may be independently for each occurrence optionally substituted with one, two,, or three halogens; wherein CrQalkyl or CVQalkoxy may be independently for each occurrence optionally substituted with one, two, or three halogens.
  • R 2i and/or R ⁇ 4 is -HL
  • R ** is selected from th group consisting of H, -Ci-
  • R" is independently for each occurrence seleeted from the group consisting of ⁇ H, -Cj-Cgalkyl, and halogen.
  • R 2 "' is selected from the group consisting of H, -O-
  • R A ' is independently for each occurrence selected from the group consisting of -H, -Ci-Cealkyl. -C . t-C ⁇ > alkoxy, and halogen.
  • Cealkyl, -C r C «aIkoxy, halogen, cyano, -COiR', -N(R C(O)Cj-C 6 alkyi s -C(0)N(R')(R"), -
  • R f is seleeted independently for each occurrence from the group consisting of -H, -Cj-Qalkyl, -CrC ⁇ alkoxy, halogen, cyano, and -OH.
  • q is 1 or 2.
  • the compound of Formula. I is represented by Formula 1-
  • R* is selected from the group consisting o -H, - €3 ⁇ 4, -CH2CH3, -CF*, -F, ⁇ CI, -Br, cyano, -OCH3 ⁇ 4 and -OCl3 ⁇ 4
  • R 2 is selected from the group consisting of ⁇ H, ⁇ C3 ⁇ 4, ⁇ F, and -OCH3; and 2 ' is selected from the group consisting of -H, - € ⁇ 3 ⁇ 4, -C3 ⁇ 4Ci3 ⁇ 4, -CH 2 CH 2 CH 2 CB*, -CF 3 , -F, -Ci, -OI L ⁇ GC3 ⁇ 4, ⁇ X3 ⁇ 4C)3 ⁇ 4, -OC(CS3 ⁇ 4) 3 , ⁇ OCB 2 CH 2 CTI 2 CH 3 , -N3 ⁇ 4, ⁇ NHCH 3 ⁇ - NHC(0)CFJ 3 , - HC(0)C i, -OCHF 2 , and -OCF3 ⁇ 4, with other R subsitituents as above.
  • R of Formula 1 , 1 -A or 1 -B is selected from the group consisting of-CH 3 , -CH(CH 3. h, -CH 2 CH 2 CH 3 ⁇ 4 -CF 3> and -C(CH 3 ) 3 ,
  • R * of Formula I, 1-A or 1-B is selected from the group consisting of -H, ⁇ CH 3j ⁇ CH 2 CH 3 , -CF 3 , -F, -CI, -Br, -CN, -OCi3 ⁇ 4, and -OCF3.
  • the present disclosure provides a method of treating, ameliorating, preventing, or substantially delaying a hepatitis B viral infection in an individual, the method comprising administering to the individual a compound or a pharmaceutical composition disclosed herein.
  • the present disclosure relates to use of a compound of Formula
  • Disclosed compounds may be prepared by methods known in the art.
  • a disclosed compound may be preparing using a method comprising providing 2,4-dichioro-6-substituted pyrimidine and a ⁇ substituted aniline group together in an organic solvent (wherein R may be selected from R l above), and then contacting a resultant compound with Z (e.g. pipera ine or 4- aniiiio aniline group).
  • HBV infection e.g. an. acute or chronic HBV infection
  • a method for treating HBV infection includes administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a disclosed compound.
  • the appropriate dosage is expected to vary depending on, for example, the particular compound employed, the mode of administration, and the nature and severit of the infection to be treated as well as the specific infection to be treated and is within the purview of the treating physician.
  • an indicated administration dose may be in the range between about 0.1 to about 15 mg/kg body weight.
  • the administration dose of the compound may be less than 10 mg kg body weight.
  • the administration dose may be less than 5 mg kg body weight.
  • the administration dose may be in the range between about 0.1 to about I rag kg body weight.
  • the dose may be conveniently administered once daily, or in divided doses up to, for example, four times a day or i sustained release town.
  • a compound or composition may be administered by any conventional route, in particular: enieraSly, topically, orally, nasally, e.g. in the form of tablets or capsules, via suppositories, or parenteral ly, e.g. in the form of injectable solutions or suspensions, for intravenous, mtra-rmiscu!ar, sub-cutaneous, or intraperitoneal injection.
  • Suitable formulations and pharmaceutical compositions will include those formulated in a conventional manner using one or more physiologically acceptable carriers or excipients, and any of those known and commercially available and currently employed in the clinical setting.
  • the compounds may be formulated for oral, buccal, topical, parenteral, rectal or transdermal administration or in a form suitable for administration by inhalation or insufflation (either orally or nasally).
  • compositions may take the form of. for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. prege latinized maize starch, polyvinylpyrrolidone or hydroxy-propyl methylcellulose); fillers (e.g. lactose, macrocrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium, starch glycoHate); or wetting agents (e.g.. sodium lauryl sulfate). Tablets may be coated by methods well known in the art.
  • pharmaceutically acceptable excipients such as binding agents (e.g. prege latinized maize starch, polyvinylpyrrolidone or hydroxy-propyl methylcellulose); fillers (e.g. lactose, macrocrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil. oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p- hydroxybenzoates or sorbic acid). Preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • suspending agents e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles
  • compositions for oral administration may also be suitably formulated to give controlled-release or sustained release of the active compound(s) over an extended period.
  • buccal administration the compositions may take the form of tablets or lozenges formulated in a conventional manner known to the skilled artisan.
  • a compound may also be formulated for parenteral administration by injection e.g. by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and ma contain additives such as suspending, stabilizing and/or dispersing agents.
  • the compound may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • Compounds ma also be formulated for rectal administratio as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • disclosed compounds may be administered as part of a combination therapy in conjunction with one or more antivirals.
  • antivirals include nucleoside analogs, interferon a, and other assembly effectors, for instance heteroaryl.dihydropyrimidi.nes (HAPs) such as methyl 4-(2-chloro-4- ⁇ luorophenyl)-6-methyl-2- (pyridm-2-yl)- 1 ⁇ -dihydropj'rimidine-S-carboxylate.
  • HAPs heteroaryl.dihydropyrimidi.nes
  • This may involve administering to a subject a first amount of a disclosed compound In combination with a second amount of an antiviral, wherein the first and second amounts together comprise a pharmaceutically effective amount.
  • the first amount, the second amount, or both may be the same, more, or less than effective amounts of each compound administered as monotherapies.
  • Therapeutically effective amounts of disclosed compound and antiviral may be co-administered to the subject, i.e., administered to the subject simultaneously or separately, in any given order and by the same or different routes of administration, in some instances, it may be advantageous to initiate administration of a disclosed compound or composition first, for example one or more days or weeks prior to initiation of administration of the antiviral.
  • additional drugs may be given in conjunction with the above combination therapy.
  • reaction was monitored by TLC; after completion the reaction, the reaction mixture was diluted with CH 2 CI 2 (30 mL), washed with water (15 mL), 1 N HCl (10 mL), 10% aHCCn solution (15 mL), brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product.
  • the precipitated material was either directly dried in vacuo or triturated or purified by column chromatography to afford the desired target compounds.
  • the reactioa was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with C3 ⁇ 4Ck (30 mL), washed with i N HC1 (15 mL), 10% NaHC0 3 solution (20 mL), water (20 mL,), dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product.
  • the crude product was washed with diethyl ether (2 x 5 mL) and «-pentane (2 x 5 mL) and dried in vacuo to afford compound 64 (110 mg, 67%) as a white solid, TLC: 5% MeOH/ CH2CI2 (Rf.
  • To a stirred solution of compound 65 (140 mg, 0.31 .mmol) in A ;i ,A' ⁇ diiuethylformam.ide ( DM F; 5 ml) under argon atmosphere were added potassium carbonate (1 10 mg, 0.79 mmol), methyl iodide (0.05 mL, 0.79 mmol) at 0 °C; warmed to 50 °C and stirred for 1 h.
  • reaction was monitored by TLC; after completion the reaction, the reaction mixture was diluted with water (20 ml.) and extracted with C3 ⁇ 4C3 ⁇ 4 (2 x 20 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product.
  • the crude product was purified through silica gel column
  • reaction was monitored by TLC: after completion of the reaction, the reaction mixture was diluted with water (30 mL) arid extracted with CHjCi? (2 x 70 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated hi vacuo to obtain the crude product. The crude product was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 72 (160 mg, 37%) as an off- white solid. TLC: 40% EtOAc/ hexanes (R/.
  • reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with C3 ⁇ 4C3 ⁇ 4 (2 x 30 mL); the combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product.
  • the crude product was purified through silica gel column chromatography using 20% EtOAc/ hexanes to afford compound 73 (40 rag, 23%) as an off-white solid.
  • TLC 30% EtOAc/ hexanes (R/.
  • the reaction was monitored by TLC; after completio of the reaction, the voiatiies were removed in vacuo to obtain the crude product.
  • the crude product was purified through silica gel column chromatography using 15% EtOAc/ hexanes to afford compound 86 (65 mg, 68%) as a low me!ting colorless solid.
  • reaction was monitored by TLC; after completion of the reaction.
  • the reaction mixture was diluted with €33 ⁇ 4 ⁇ 3 ⁇ 4 (20 mL) and washed with 2 N HC! (2 x 10 mL).
  • the organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product, which was precipitated with 20% EtOAc/ hexanes to afford 29 (25 mg, 45%) as an oil- white solid.
  • TLC 5% CH 3 OH/ CH 2 C1 2 ⁇ Rf.
  • Compound 9 may aiso be prepared from trichloropyrinridine and isopropyl magnesium chloride as described above.
  • reaction was monitored by TLC; after completion of the reaction, the reaction mixture was diluted with water (15 mL), the pM was adjusted to ⁇ 8 with aqueous saturated NaHCOj solution (10 mL), and extracted with EtOAc (2 x 30 mL), The combined organic extracts were dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude compound 95 (50 mg, 87%) as white solid.
  • reaction was monitored by T LC; after completion of the reaction, the reaction mixture was diluted with €3 ⁇ 4(3 ⁇ 4 (30 raL) and washed with I HCI (10 mL), followed by aqueous saturated NaHC ⁇ 3 ⁇ 4 solution (10 mL). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product, which was triturated with 2% Q3 ⁇ 4CI? »- pentane to afford 31 (30 mg, 40%) as a white solid, TLC: 5% CH3OH/ CH 2 C1 2 (Rf.
  • reaction was monitored by TLC: after completion of the reaction, the reaction mixture was dilated with Q3 ⁇ 4(3 ⁇ 4 (15 mL), washed with 10% aqueous NaHC(1 ⁇ 4 solution (10 mL) and 1 N HC1 (2 15 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to obtain the crude product which was triturated with 5% EtOAc/ «-pentane (2 x 5 mL) to afford 33 (35 mg, 47%) as an off-white solid.
  • reaction was monitored by TLC; after completion of the reac tion, the reaction mixture was diluted with ice cold water (20 mL) and the pH was iieuiralized with 6 N HCL The precipitated solid was filtered, washed with EtOAc (2 x 5 mL), water (2 x 10 mL) and dried in vacuo to afford compound 172 (1 g, 62%) as a yello syrup.
  • TLC 40% EtOAc/ hexane (Rf.
  • Target compound ' 5 is shown below and ma be prepared by known methods
  • a screening for assembly effector activity was conducted based on a fluorescence quenching assay developed in the Ziotnick lab (Stray t al. y 2006; Ziotnick ei a/., 2007).
  • a Cp mutant is specifically labeled with a fluorescent dye. In the dimeric state fluorescence is intense. However, when the Cp assembles, the dye moiecuies accumulate at fivefold and quasi-sixfold vertices to self quench by up to 95%.
  • M the high throughput screen, the Cp concentration is chosen so that addition ofNaCl, typically 150 jnM or 300 ni is sufficient to induce about 25% assembly. Thus, assembly effectors that enhance assembly are readily detected.
  • I ' etracycl e-free treatment medium 15 mL DMEM/F12 (1: 1) (cat S 30023.01, Hycione, x Pen/step (cat#; 30- 002-CL, Medtatech, Inc), with 2% BS, Tet-system approved (cat#; 631 106, Clontech) were then added to mix and spun at ⁇ 300 rpm for 5 min. Pelleted cells were then re- suspended/ washed with 50 mL of .1 BS 2 times and 10 mL treatment medium one time.
  • AD38 cells were then re-suspended with 10 mL of treatment medium and counted.
  • Well of a collagen coated 96-we!i NUNC microliter plate were seeded at 50,000/well in 180 ⁇ . of treatment medium, and 20 ⁇ of either 10% DMSO (Control) or a iOX solution of test compound in 1 % DMSO in treatment media was added for a final compound concentration 1, 3, or 10 ⁇ . (1 ,0% final [DMSO]) and plates were incubated for 5 days at 37 °C.
  • Viral load was quantitated against known standards by using Vii ATM 7 Software. Viral load in the supernatant from wells with treated cells were compared against viral load in supernatant from DMSO control wells (> 3 per plate), hi Table 4, concentrations of test compound causing reductions in viral load greater than at least 3 standard deviations from the DMSO controls across all plates were consideired active, with (+) depicting meets criteria for significant activity, and ( ⁇ + ⁇ +) depicting exceeds criteria.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouveaux composés d'effecteurs d'assemblage possédant un effet thérapeutique contre une infection par le virus de l'hépatite B (VHB). Les molécules d'effecteur d'assemblage précitées peuvent conduire à un assemblage viral défectueux et affecter également d'autres activités virales associées à une infection chronique par le HBV. L'invention concerne également un processus de synthèse des composés précités, un procédé de traitement de VHB par administration des composés précités et l'utilisation de ces composés pour produire des médicaments contre le VHB.
EP14853713.7A 2013-10-18 2014-10-16 Effecteurs d'assemblage de virus de l'hépatite b Not-in-force EP3057592B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361892591P 2013-10-18 2013-10-18
PCT/US2014/060869 WO2015057945A1 (fr) 2013-10-18 2014-10-16 Effecteurs d'assemblage de virus de l'hépatite b

Publications (3)

Publication Number Publication Date
EP3057592A1 true EP3057592A1 (fr) 2016-08-24
EP3057592A4 EP3057592A4 (fr) 2017-04-19
EP3057592B1 EP3057592B1 (fr) 2019-05-22

Family

ID=52828690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14853713.7A Not-in-force EP3057592B1 (fr) 2013-10-18 2014-10-16 Effecteurs d'assemblage de virus de l'hépatite b

Country Status (7)

Country Link
US (1) US10220034B2 (fr)
EP (1) EP3057592B1 (fr)
CN (1) CN105828823B (fr)
AU (1) AU2014337298B2 (fr)
CA (1) CA2927560A1 (fr)
ES (1) ES2739435T3 (fr)
WO (1) WO2015057945A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
UA123256C2 (uk) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Сульфамоїлариламіди та їх застосування як лікарських препаратів для лікування гепатиту b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
ES2640063T3 (es) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JP6348978B2 (ja) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー グリオキサミド置換ピロールアミド誘導体およびｂ型肝炎を処置するための医薬品としてのその使用
ES2655518T3 (es) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
EP3283472B1 (fr) * 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (fr) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Formes cristallines d'un agent antiviral de l'hépatite b
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EP3454856B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
EP3704127A1 (fr) 2017-11-02 2020-09-09 AiCuris GmbH & Co. KG Nouveaux indole-2-carboxamides à substitution amino-thiazole hautement actifs agissant contre le virus de l'hépatite b (vhb)
SG11202003746UA (en) 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
CA3090125A1 (fr) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Schema posologique de modulateur d'assemblage de capside
UY38434A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
AR116947A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR116946A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
AU2019373679A1 (en) 2018-11-02 2021-05-27 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV)
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
AR116948A1 (es) 2018-11-02 2021-06-30 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
WO2020132561A1 (fr) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Dégradation ciblée de protéines
MX2021013085A (es) 2019-04-30 2021-11-17 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb).
EP3962909B1 (fr) 2019-04-30 2023-10-04 AiCuris GmbH & Co. KG Nouvelles pipérazines d'oxalyle actives contre le virus de l'hépatite b (vhb)
US20220227789A1 (en) 2019-04-30 2022-07-21 Aicuris Gmbh & Co. Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
EP3962912A1 (fr) 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Nouvelles urées de phényle et de pyridyle actives contre le virus de l'hépatite b (vhb)
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
GB202014736D0 (en) * 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004776A1 (fr) 2004-06-29 2006-01-12 Rigel Pharmaceuticals, Inc. Composés de 4-pyrimidineamine et leurs utilisations en tant qu’agent anti-prolifération
US20060293343A1 (en) 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
DE602005018972D1 (de) 2005-09-23 2010-03-04 Equispharm Co Ltd 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
WO2010118367A2 (fr) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Pyrimidines antivirales
AU2011249859B2 (en) * 2010-05-07 2014-07-03 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
WO2012143144A1 (fr) 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
US9487534B2 (en) * 2011-08-02 2016-11-08 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
US9637491B2 (en) 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors

Also Published As

Publication number Publication date
EP3057592A4 (fr) 2017-04-19
CN105828823B (zh) 2019-06-14
ES2739435T3 (es) 2020-01-31
US10220034B2 (en) 2019-03-05
CN105828823A (zh) 2016-08-03
WO2015057945A1 (fr) 2015-04-23
AU2014337298B2 (en) 2018-12-06
CA2927560A1 (fr) 2015-04-23
EP3057592B1 (fr) 2019-05-22
AU2014337298A1 (en) 2016-05-05
US20160271130A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
WO2015057945A1 (fr) Effecteurs d'assemblage de virus de l'hépatite b
EP3283472B1 (fr) Effecteurs d'assemblage de virus de l'hépatite b
EP2651899B1 (fr) Composés hétérocycliques azotés substitués 6,6-fusionnés et leurs utilisations
WO2021087018A1 (fr) Pyridazinones utilisées en tant qu'inhibiteurs de parp7
JP2019023192A (ja) ブロモドメイン阻害剤
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
JP2010514676A (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
CZ20031125A3 (cs) Nové sloučeniny
WO2012008564A1 (fr) Dérivé cyclique hétérocyclique aromatique azoté
JPWO2012008563A1 (ja) 含窒素芳香族複素環誘導体
CA3083122A1 (fr) Composes heteroaryle a substitution sulfone pyridine d'alkyle amide
JP2006504728A (ja) ピラソロピリジン誘導体系治療用化合物
CN101679426A (zh) 9-(吡唑-3-基)-9H-嘌呤-2-胺和3-(吡唑-3-基)-3H-咪唑并[4,5-b]吡啶-5-胺衍生物和它们治疗癌症的用途
JP2022532877A (ja) Ｊａｋ阻害剤
JP6913955B2 (ja) ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物
JP2017160244A (ja) ヒト呼吸器多核体ウイルス（ｒｓｖ）の阻害剤として有用なジアミノピリミジン
JP2006525281A (ja) ピリジニルアセトニトリル類
EP3087060B1 (fr) Composés pyrimidone carboxamide utilisés en tant qu'inhibiteurs de pde2
EP2716639A1 (fr) Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
EA043549B1 (ru) Стимуляторы sgc
WO2023244672A1 (fr) Dérivés de 2-(imidazo[1,2-a]1,8-naphtyridin-8-yl)-1,3,4-oxadiazole en tant qu'activateurs de réponse immunitaire innée pour le traitement d'infections virales
WO2022010882A1 (fr) Dérivés de dihydroquinoxaline et de dihydropyridopyrazine utilisés comme inhibiteurs de rsv
WO2010066253A1 (fr) Inhibiteurs sélectifs du sous-type 1 du transporteur d'acides aminés excitateurs (eaat1/glast)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170316

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/535 20060101AFI20170311BHEP

Ipc: A61K 31/497 20060101ALI20170311BHEP

Ipc: C07D 413/00 20060101ALI20170311BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180319

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181204

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZLOTNICK, ADAM

Inventor name: FRANCIS, SAMSON

Inventor name: LI, LICHUN

Inventor name: TURNER, WILLIAM JR.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014047399

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1135258

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190615

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190522

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190922

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190822

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190822

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190823

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1135258

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2739435

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014047399

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

26N No opposition filed

Effective date: 20200225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191016

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191016

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20201103

Year of fee payment: 7

Ref country code: GB

Payment date: 20201027

Year of fee payment: 7

Ref country code: FR

Payment date: 20201026

Year of fee payment: 7

Ref country code: IT

Payment date: 20201023

Year of fee payment: 7

Ref country code: DE

Payment date: 20201028

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190922

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20141016

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602014047399

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20211016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211016

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211016

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20230210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211017